Browsing by Author "Abukhattab, Mohammed"
Now showing items 1-2 of 2
-
Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
Rahhal, Alaa; Najim, Mostafa; Aljundi, Amer Hussein; Mahfouz, Ahmed; Alyafei, Sumaya Mehdar; Awaisu, Ahmed; Habib, Mhd, Baraa; Obeidat, Ibrahim; Faisal, Mohanad Mohammed; Alanzi, Meshaal Ali; Nair, Arun Prabhakaran; Elhassan, Areeg; Al-Dushain, Abdullah; Abdelmajid, Alaaeldin Abdelmajid; Abdelgader, Ahmed Elfadil; Moursi, Ahmed Mahmoud Ahmed; Alharafsheh, Ahmad Eid Nazzal; Kamar, Mohd Ragheb Abou; Goravey, Wael; Omar, Amr Salah; Abukhattab, Mohammed; Khatib, Mohamad Yahya; Mohamedali, Mohamed Gaafar; AlMaslamani, Muna A. Rahman; Alemadi, Samar... more authors ... less authors ( Lippincott Williams and Wilkins , 2022 , Article)Introduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result ... -
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Ahmed, Zaqout; Almaslamani, Muna A.; Chemaitelly, Hiam; Hashim, Samar A.; Ittaman, Ajithkumar; Alimam, Abeir; Rustom, Fatma; Daghfal, Joanne; Abukhattab, Mohammed; AlMukdad, Sawsan; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Butt, Adeel A.; Bertollini, Roberto; Al-Khal, Abdullatif; Omrani, Ali S.; Abu-Raddad, Laith J.... more authors ... less authors ( Elsevier , 2022 , Article)ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ...